Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.22
- Piotroski Score 4.00
- Grade Underweight
- Symbol (VAPO)
- Company Vapotherm, Inc.
- Price $2.17
- Changes Percentage (-0.46%)
- Change -$0.01
- Day Low $2.17
- Day High $2.17
- Year High $3.44
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $128.00
- High Stock Price Target $128.00
- Low Stock Price Target $128.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$8.39
- Trailing P/E Ratio -0.1
- Forward P/E Ratio -0.1
- P/E Growth -0.1
- Net Income $-58,193,000
Income Statement
Quarterly
Annual
Latest News of VAPO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Support for nuclear power will evaporate at next election, Chris Bowen says
Australian support for nuclear power may decline as voters realize the Coalition's policy favors old coal plants, risking blackouts. Research shows public preference for renewables over nuclear energy...
By The Guardian | 1 month ago -
Support for Erik ten Hag has evaporated after the lowest moment of his Man United tenure
The managerial cycle at Manchester United continues with Erik ten Hag now facing scrutiny after two years. Despite initial success, recent poor performances have led to fan backlash and calls for chan...
By The New York Times | 2 months ago -
Democrats' advertising advantage evaporates in key Ohio Senate race
In the Ohio Senate race, Republicans have ramped up ad spending, erasing Democrats' previous advantage. GOP nominee Bernie Moreno and allies are outspending Sen. Sherrod Brown, making the race for Sen...
By NBC News | 2 months ago